Low-dose oral methotrexate for the management of childhood Cogan's syndrome: a case report.

Abstract

Cogan's syndrome is a rare inflammatory disease characterized by nonsyphilitic ocular interstitial keratitis associated with hearing loss and vestibular impairment. Although systemic corticosteroids are usually used as the standard therapy, hearing ability in most cases gradually deteriorates. We, herein, describe a patient with childhood Cogan's syndrome who was treated with low-dose oral methotrexate, which successfully helped to taper the doses of the systemic corticosteroids. The serum levels of the complements were good markers for the disease activity in this patient.

• Authors: Yuzaburo Inoue, Takuya Tomemori, Shuichi Suzuki, Takayasu Arima, Minako Tomiita, Naoki Shimojo, Yoichi Kohno
• Journal: Clinical rheumatology (Clin Rheumatol) Vol. 26 Issue 12 Pg. 2201-2203 (Dec 2007) ISSN: 0770-3198 [Print] Germany
• PMID: 17611707 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunosuppressive Agents
• Methotrexate

Topics

• Administration, Oral
• Child
• Disease Progression
• Follow-Up Studies
• Hearing Loss, Sensorineural (complications, drug therapy)
• Humans
• Immunosuppressive Agents (administration & dosage)
• Keratitis (complications, drug therapy)
• Male
• Methotrexate (administration & dosage)
• Syndrome